SLGL - Sol-Gel Technologies Announces Last Patient Last Visit in Pivotal Phase 3 Clinical Trial of SGT-610 in Gorlin Syndrome
SLGL - Sol-Gel Technologies Announces Last Patient Last Visit in Pivotal Phase 3 Clinical Trial of SGT-610 in Gorlin Syndrome